Gowling WLG advises Crescendo Biologics on collaboration with Takeda worth up to $790 million
Gowling WLG's Life Sciences team, led by partner Patrick Duxbury and including associate Kathryn Charles, have advised client Crescendo Biologics on its collaboration with Takeda Pharmaceutical Company Limited to discover, develop and commercialise Humabody®-based therapeutics aimed at cancer indications with a high unmet medical need.